Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
endocrine-modulating drug therapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| endocrine-modulating drug therapy | DRUG | - |
| mitoxantrone hydrochloride | DRUG | - |
| prednisone | DRUG | - |
| prinomastat | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed metastatic, hormone refractory prostate cancer Must have undergone prior orchiectomy or treatment with an LHRH analog Prior treatment with an antiandrogen agent (e.g., flutamide or bicalutamide) is optional Castrate serum testosterone no greater than...
Top 20 of 53 competitors
Endocrine-modulating drug therapy is used for the treatment of prostate cancer, specifically in patients with metastatic disease. It is an investigational small molecule therapy being studied in a Phase 3 clinical trial. The therapy is designed to modulate endocrine pathways that may influence cancer progression.
Endocrine-modulating drug therapy is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the therapy's safety and efficacy in patients with metastatic prostate cancer.
Endocrine-modulating drug therapy is in Phase 3 clinical development for prostate cancer. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the therapy remains under evaluation for potential future use.
Endocrine-modulating drug therapy has been studied in one completed Phase 3 clinical trial, identified as NCT00003343. This trial, titled 'Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer,' enrolled 525 male patients aged 18 years and older in the United States. The trial was uncontrolled and not double-blinded.
Endocrine-modulating drug therapy is not the same as chemotherapy. It is a distinct small molecule therapy that targets endocrine pathways, whereas chemotherapy directly kills rapidly dividing cells. The Phase 3 trial NCT00003343 evaluated the therapy in patients with metastatic prostate cancer, but the therapy's mechanism differs from traditional chemotherapy.